glp-1 long-term risks long term effects of glp 1 use Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Do The Benefits of GLP-1

What is the FDA-approved use of Foundayo

Third, we did not account for earlier disease stages, such as advanced chronic kidney disease, nor did we account for side-effects of these medications

FDA Crackdown on Compounded GLP-1s (Regulatory): On February 6, 2026, the FDA announced a formal intent to restrict the use of active pharmaceutical ingredients (APIs) for non-approved compounded GLP-1 drugs, targeting "mass-marketed" alternatives from companies like Hims & Hers as the national supply of brand-name versions stabilized

We did not include individuals treated with insulin alone as an active comparator as it would introduce a significant amount of bias with the lack of a codable index event (i.e

Currently, many clinical practice guidelines, including the consensus guideline of the American Diabetes Association and the European Association for the Study of Diabetes, recommend glucagon-like peptide-1 receptor agonist (GLP-1RA) as the first-line injectable agent ahead of basal insulin for most patients with T2DM ( So far, two different products containing fixed-ratio combinations (FRCs) of basal insulin and GLP-1RA were approved by the US Food and Drug Administration and European Medicines Agency: IGlarLixi, which is a combo of insulin glargine and lixisenatide, and IDegLira, which is a combo of insulin degludec and liraglutide ( Based on these backgrounds, this study aimed to evaluate the overall effect of adding basal insulin on persisting GLP-1RA treatment